Sort
11,323 grants matching “glioblastoma”
The Fox M1 in Human Glioma Development and Progression
$218,680Suyun Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2006 · CA
Investigating and Targeting TAMs in the Glioma Microenvironment
$218,655Johanna Joyce · University Of Lausanne · R01 · FY2018 · CA
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
$218,604Charles S Cobbs · Swedish Medical Center, First Hill · R21 · FY2024 · CA
Armed oncolytic parvoviral vectors for modulating the tumor microenvironment
$218,588Peter Tattersall · Yale University · R21 · FY2020 · CA
Molecular mechanism of PID1, a novel tumor inhibitor, in glioblastomas
$218,531Anat Erdreich-Epstein · Children'S Hospital Of Los Angeles · R21 · FY2015 · NS
Investigating Pathophysiology of Glioma Stem Cells in 3D Bioprinted Vascularized Glioblastoma Model
$218,462Irtisha Singh · Texas A&M University Health Science Ctr · R21 · FY2022 · NS
SUPPRESSION OF HUMAN GLIOBLASTOMA CELL GROWTH BY CX43
$218,432Emory University · R01 · FY2000 · CA
Identification of RhoGEFs as novel therapeutic targets for malignant glioma
$218,204Marc H Symons · Feinstein Institute For Medical Research · R21 · FY2007 · NS
Dynamics of Uracil Accumulation in Human Cellular DNA
$218,140Samuel E Bennett · Oregon State University · R01 · FY2006 · GM
Redox manipulation of iron to improve glioblastoma therapy: A phase 1 trial
$218,089Bryan Allen · University Of Iowa · R21 · FY2023 · CA
Identification and Characterization of Kinase Oncogenes in Glioblastoma
$217,878Lynda Chin · Dana-Farber Cancer Inst · P01 · FY2008 · CA
Mechanisms of Herbal Radiosensitization of Glioma Cells
$217,868California Pacific Med Ctr Res Institute · R01 · FY2000 · AT
Administrative and Clinical Services Core
$217,863Susan M Chang · University Of California, San Francisco · P01 · FY2015 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$217,832Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2014 · CA
Metabolic reprogramming to improve EGFRvIII CAR T cell persistence
$217,753Nancie Maciver · Univ Of North Carolina Chapel Hill · R21 · FY2022 · CA
Examining the role of XRN2 in radio and chemo-resistance
$217,500Julio Cesar Morales · University Of Oklahoma Hlth Sciences Ctr · P20 · FY2018 · GM
Blood-based assays for the detection of glioblastoma RNA biomarkers
$217,500Bakhos A. Tannous · Massachusetts General Hospital · R21 · FY2016 · NS
Analysis of Migration Associated Treatment Resistance in Glioblastoma to Identify Novel Therapeutics
$217,500James Battiste · University Of Oklahoma Hlth Sciences Ctr · P20 · FY2018 · GM
Deciphering MDSC function for GBM targeting
$217,469Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · NS
Deciphering MDSC function for GBM targeting
$217,469Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · NS
Development of A Directed Evolution Platform for RNA Methyltransferases.
$217,388Huiqing Zhou · Boston College · R61 · FY2024 · CA
Development of A Directed Evolution Platform for RNA Methyltransferases.
$217,388Huiqing Zhou · Boston College · R61 · FY2025 · CA
Collaborative Systems for Analyzing Tissue Microarrays
$217,284David J Foran · Rbhs-Robert Wood Johnson Medical School · R01 · FY2014 · CA
Therapeutic Evaluation of Magnetic Nanoprobes Specific for Malignant Tumor Marker
$217,163Rheal A Towner · Oklahoma Medical Research Foundation · R21 · FY2010 · CA
Development of Transporter Targeted Platinum Drugs for Glioblastoma
$216,990Huan-Chieh Chien · Apricity Therapeutics, Inc. · R43 · FY2016 · CA